Genprex’s $8 Million Common Stock Offering

Sheppard, Mullin, Richter & Hampton LLP advised Genprex, Inc.

Genprex, Inc., a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, issued a $8.0 million registered direct offering of common stock.

Genprex’s common stock is listed on the Nasdaq Capital Market under the symbol “GNPX.”

The Sheppard Mullin team, led by partner Richard Friedman (Picture), included partner Stephen Cohen and associates Nazia Khan, Alexander Yarbrough, and Matthew Hayes.

Involved fees earner: Stephen Cohen – Sheppard Mullin; Richard Friedman – Sheppard Mullin; Matthew Hayes – Sheppard Mullin; Nazia Khan – Sheppard Mullin; Alexander Yarbrough – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Genprex, Inc.;

Print Friendly, PDF & Email

Author: Ambrogio Visconti